Author:
Chen Yi-Cheng,Hsu Chao-Wei,Chien Rong-Nan,Tai Dar-In
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference27 articles.
1. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy;Murakami;Antimicrob Agents Chemother,2015
2. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection;Agarwal;J Hepatol,2015
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial;Buti;Lancet Gastroenterol Hepatol,2016
4. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial;Chan;Lancet Gastroenterol Hepatol,2016
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study;Lampertico;Lancet Gastroenterol Hepatol,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献